APGOT was formed in 2019 with the idea of consolidating collaborations among a cadre of highly-experienced and like-minded clinical investigators from well-established, country-specific clinical research networks that are committed to performing gynecological cancer focused clinical trials and training the next generation of clinician investigators. The consortium was initially comprised of the Korean Gynecologic Oncology Group (KGOG), the Gynecologic Cancer Group Singapore (GCGS) and the Australian-New Zealand Gynecologic Oncology Group (ANZGOG) and GOTIC (North Kanto Gynecologic Cancer Clinical Trials Consortium) from Japan. Now Kolkata Gynecological Oncology Trials and Translational Research Group (KolgoTrg), Shanghai Gynecologic Oncology Group (SGOG) have joined. We also invited Taiwan Gynecologic Oncology Group (TGOG) and Asian Gynecologic Oncology Group (AGOG) to join.
The APGOT mission is to provide an international platform for collaborative efforts to develop better treatments for patients with gynecological cancers, and to enable good translational science to impact positively on patient outcomes, thus improving health outcomes for all women globally.
Our vision is to advance research and development of therapeutics and diagnostics in gynecological cancers through APGOT by facilitating the conduct of investigator-initiated and pharma-sponsored studies testing novel therapeutic and diagnostic strategies across a large and ethnically diverse patient population in the Asia-Pacific Region. In particular, we focus to perform well designed precision medicine with excellent translational research in gynecologic oncology through vigorous cooperation among our groups. To this end, we will also aim to continually expand our network of research collaborators from other countries within the Asia-Pacific Region and beyond as well.